Get started
Foghorn Therapeutics Inc.Foghorn Therapeutics Inc.Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

FHTX chart


Full chart

FHTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪506.45 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.91 USD
Net income (FY)
‪−98.43 M‬ USD
Revenue (FY)
‪34.16 M‬ USD
Shares float
‪28.59 M‬
Beta (1Y)
3.48

Employees


Employees (FY)
116
Change (1Y)
−45 −27.95%
Revenue / Employee (1Y)
‪294.44 K‬ USD
Net income / Employee (1Y)
‪−848.50 K‬ USD

About Foghorn Therapeutics Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Adrian Gottschalk
Website
foghorntx.com
Headquarters
Cambridge
Founded
2015
FIGI
BBG00HFZPB88
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

FHTX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where FHTX is featured.

See all sparks 

Frequently Asked Questions


The current price of FHTX is 9.20 USD — it has increased by 0.33% in the past 24 hours. Watch Foghorn Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Foghorn Therapeutics Inc. stocks are traded under the ticker FHTX.
FHTX stock has risen by 17.78% compared to the previous week, the month change is a 20.42% rise, over the last year Foghorn Therapeutics Inc. has showed a 161.97% increase.
We've gathered analysts' opinions on Foghorn Therapeutics Inc. future price: according to them, FHTX price has a max estimate of 20.00 USD and a min estimate of 9.00 USD. Watch FHTX chart and read a more detailed Foghorn Therapeutics Inc. stock forecast: see what analysts think of Foghorn Therapeutics Inc. and suggest that you do with its stocks.
FHTX reached its all-time high on Dec 18, 2020 with the price of 28.27 USD, and its all-time low was 2.70 USD and was reached on Feb 5, 2024. View more price dynamics on FHTX chart.
See other stocks reaching their highest and lowest prices.
FHTX stock is 3.68% volatile and has beta coefficient of 3.48. Track Foghorn Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Foghorn Therapeutics Inc. there?
Today Foghorn Therapeutics Inc. has the market capitalization of ‪504.04 M‬, it has increased by 5.24% over the last week.
Yes, you can track Foghorn Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Foghorn Therapeutics Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
FHTX earnings for the last quarter are −0.31 USD per share, whereas the estimation was −0.43 USD resulting in a 27.91% surprise. The estimated earnings for the next quarter are −0.36 USD per share. See more details about Foghorn Therapeutics Inc. earnings.
Foghorn Therapeutics Inc. revenue for the last quarter amounts to ‪7.80 M‬ USD, despite the estimated figure of ‪6.34 M‬ USD. In the next quarter, revenue is expected to reach ‪7.08 M‬ USD.
FHTX net income for the last quarter is ‪−19.12 M‬ USD, while the quarter before that showed ‪−22.98 M‬ USD of net income which accounts for 16.78% change. Track more Foghorn Therapeutics Inc. financial stats to get the full picture.
No, FHTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 116.00 employees. See our rating of the largest employees — is Foghorn Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Foghorn Therapeutics Inc. EBITDA is ‪−98.55 M‬ USD, and current EBITDA margin is −290.57%. See more stats in Foghorn Therapeutics Inc. financial statements.
Like other stocks, FHTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Foghorn Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Foghorn Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Foghorn Therapeutics Inc. stock shows the buy signal. See more of Foghorn Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.